Resources from the same session
855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
Presenter: Caroline Even
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
856MO - A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis
Presenter: Dan Zandberg
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
Presenter: Nicolas Mach
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial
Presenter: Loren Michel
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
860MO - MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
Presenter: Fei Han
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA47 - A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
Presenter: Alan Ho
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 859MO, 860MO and LBA47
Presenter: Marc Oliva
Session: Mini oral session - Head and neck cancer
Resources:
Slides
Webcast